Patents by Inventor Helmut Wurst
Helmut Wurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11065364Abstract: A combination comprising, spatially separate from one another, a first component and a second component, where the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially, more particularly only partially, an albumin-crosslinking group. Additionally disclosed is a reaction product obtainable by means of the combination, to a medical device, to a medicinal product for innovative therapies, to a kit, to a discharge apparatus, and to a functionalized hyaluronic acid.Type: GrantFiled: August 28, 2017Date of Patent: July 20, 2021Assignee: TETEC Tissue Engineering Technologies AGInventors: Helmut Wurst, Nils Clausen, Nina Baldassi
-
Patent number: 10500154Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.Type: GrantFiled: July 27, 2010Date of Patent: December 10, 2019Assignee: NMI NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGENInventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
-
Publication number: 20190367869Abstract: A 3D culture system based on chemically defined hydrogel scaffolds for the cultivation and expansion of pancreas-type organoids from isolated pancreatic cells in vitro.Type: ApplicationFiled: May 30, 2019Publication date: December 5, 2019Inventors: Brigitte ANGRES, Nadine RISCHERT, Helmut WURST
-
Publication number: 20190192733Abstract: A combination comprising, spatially separate from one another, a first component and a second component, where the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially, more particularly only partially, an albumin-crosslinking group. Additionally disclosed is a reaction product obtainable by means of the combination, to a medical device, to a medicinal product for innovative therapies, to a kit, to a discharge apparatus, and to a functionalized hyaluronic acid.Type: ApplicationFiled: August 28, 2017Publication date: June 27, 2019Inventors: Helmut WURST, Nils CLAUSEN, Nina BALDASSI
-
Patent number: 10196602Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.Type: GrantFiled: January 11, 2010Date of Patent: February 5, 2019Assignee: NMI NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGENInventor: Helmut Wurst
-
Publication number: 20180311376Abstract: The invention relates to medical compositions, a medical hydrogel, a medical kit and a multichamber discharge device for use in the prevention and/or treatment of a disease of the facet joints and/or in the replacement and/or regeneration of articular facets.Type: ApplicationFiled: October 20, 2016Publication date: November 1, 2018Inventors: Helmut Wurst, Christoph Gaissmaier, Nils Clausen
-
Patent number: 8952095Abstract: A peptide cross-linking agent in the form of a linear molecule has a molecular mass of 3 to approximately 60 kDa. The peptide cross-linking agents are used for cross-linking functionalized polymers to form hydrogels having two or more components.Type: GrantFiled: February 4, 2011Date of Patent: February 10, 2015Assignee: CELLENDES GmbHInventors: Helmut Wurst, Karima Larbi, Markus Herrmann
-
Publication number: 20150038681Abstract: A method of preparing a product, preferably in the form of a functionalized high molecular weight component such as, for example, a functionalized protein includes passing a first liquid comprising a component A along one side of a semi-permeable membrane and passing a second liquid comprising a component B along another, preferably opposing, side of the membrane, wherein the membrane excludes passage of component A but allows passage of component B, and after passage of component B through the membrane, a chemical reaction takes place between component A and component B, preferably with the formation of covalent bonds.Type: ApplicationFiled: August 4, 2014Publication date: February 5, 2015Inventors: Juergen Mollenhauer, Heinz W. Joseph, Helmut Wurst
-
Publication number: 20130052736Abstract: A peptide cross-linking agent in the form of a linear molecule has a molecular mass of 3 to approximately 60 kDa. The peptide cross-linking agents are used for cross-linking functionalized polymers to form hydrogels having two or more components.Type: ApplicationFiled: February 4, 2011Publication date: February 28, 2013Applicant: CELLENDES GmbHInventors: Helmut Wurst, Karima Larbi, Markus Herrmann
-
Publication number: 20100322993Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.Type: ApplicationFiled: July 27, 2010Publication date: December 23, 2010Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
-
Publication number: 20100184223Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.Type: ApplicationFiled: January 11, 2010Publication date: July 22, 2010Inventor: Helmut Wurst
-
Publication number: 20020173016Abstract: High throughput lyophilized polymerase devices and methods for their use in the production of nucleic acids using template dependent polymerase reactions are provided. The subject devices are typically made up of a multi-well substrate that includes in a least one well a lyophilized nucleic acid polymerase composition. The subject nucleic acid polymerase compositions include at least one polymerase and a carbohydrate stabilizing composition that is made up of at least one low molecular weight sugar and a starch. In many embodiments, the compositions also include buffer components and nucleotides, as well as a temperature dependent polymerase inhibitor, e.g., a polymerase specific antibody. Also provided are kits that include the subject devices.Type: ApplicationFiled: March 27, 2001Publication date: November 21, 2002Inventors: Helmut Wurst, Ningyue Zhao
-
Publication number: 20020119465Abstract: Enzyme compositions, kits comprising the same and methods for their use in one-step RT-PCR are provided. The subject enzyme compositions at least include a mutant thermostable DNA polymerase and a mutant reverse transcriptase. In preferred embodiments, the mutant thermostable DNA polymerase is an N-terminal deletion mutant of Taq polymerase and the mutant reverse transcriptase is a point mutation mutant of MMLV-RT. The subject kits, in addition to the above described mutant thermostable DNA polymerase and mutant reverse transcriptase, at least include one of, and usually both of, dNTPs and a buffer composition, where the subject kits may further include additional reagents, including nucleic acids, a thermostabilizing agent, a glycine based osmolyte and the like. In practicing the subject methods, a reaction mix that at least includes template RNA, the above described mutant polymerase and reverse transcriptase, dNTPs, buffer, and nucleic acid primers is prepared.Type: ApplicationFiled: August 16, 2001Publication date: August 29, 2002Inventors: Ningyue Zhao, Helmut Wurst
-
Patent number: 6383755Abstract: Methods are provided for evaluating the fidelity of a given set of polymerase chain reaction conditions. In the subject methods, a template polydeoxyribonucleotide is amplified under the to be evaluated polymerase chain reaction conditions, where the template polydeoxyribonucleotide includes a pseudo restriction endonuclease restriction site. The resultant amplified product population is then contacted with the corresponding restriction endonuclease and resultant cleavage products, if any, are detected. The fidelity of the polymerase chain reaction conditions is then derived from the detected cleavage products (or absence thereof). Also provided are kits for use in practicing the subject methods. The subject methods are suited for determining the fidelity of a given polymerase under PCR conditions, and are particularly suited for determining the fidelity of a thermostable polymerase under PCR conditions.Type: GrantFiled: September 6, 2000Date of Patent: May 7, 2002Assignee: Clontech Laboratories, Inc.Inventors: Gregory D. Davis, Helmut Wurst
-
Patent number: 6300073Abstract: Enzyme compositions, kits comprising the same and methods for their use in one-step RT-PCR are provided. The subject enzyme compositions at least include a mutant thermostable DNA polymerase and a mutant reverse transcriptase. In preferred embodiments, the mutant thermostable DNA polymerase is an N-terminal deletion mutant of Taq polymerase and the mutant reverse transcriptase is a point mutation mutant of MMLV-RT. The subject kits, in addition to the above described mutant thermostable DNA polymerase and mutant reverse transcriptase, at least include one of, and usually both of, dNTPs and a buffer composition, where the subject kits may further include additional reagents, including nucleic acids, a thermostabilizing agent, a glycine based osmolyte and the like. In practicing the subject methods, a reaction mix that at least includes template RNA, the above described mutant polymerase and reverse transcriptase, dNTPs, buffer, and nucleic acid primers is prepared.Type: GrantFiled: October 1, 1999Date of Patent: October 9, 2001Assignee: Clontech Laboratories, Inc.Inventors: Ningyue Zhao, Helmut Wurst
-
Patent number: 6130045Abstract: A thermostable enzyme having polymerase activity and substantially no nuclease activity is provided. The thermostable enzyme is characterized by comprising a sequence of nine amino acid residues at least proximal to the N-terminus that has less than 50% but greater than 40% amino acid sequence identity with residues 280 to 288 of the naturally occurring Thermus aquaticus polymerase. The subject enzyme finds use in a variety of different application in which polynucleotides are enzymatically produced, particularly in PCR based applications.Type: GrantFiled: June 11, 1998Date of Patent: October 10, 2000Assignee: Clontech Laboratories, Inc.Inventors: Helmut Wurst, Zhi-Hao Qiu
-
Patent number: 5976842Abstract: Methods and compositions are provided for performing high fidelity polymerase chain reactions. In the subject methods, primer extension products are produced with a low error frequency rate through the use of at least one of unequal concentrations of dNTPs or a melting point reducing agent. Also provided are kits and reagent mixtures for use in the subject methods. The subject invention finds use in a variety of applications, particularly in applications where high fidelity PCR is desired.Type: GrantFiled: October 30, 1997Date of Patent: November 2, 1999Assignee: Clontech Laboratories, Inc.Inventor: Helmut Wurst